Reviews/Chronic Pain Pharmacotherapy/Gabapentinoids in non-neuropathic pain
Gab · CPP-GAB-03 · v2
Borderline: within 4 points of the Likely/Uncertain boundary, so a re-grade could land either side.
This claim asks whether gabapentinoids (gabapentin and pregabalin) do little to relieve chronic pain that is not nerve-pain. The usable human trials in the corpus lean toward 'little benefit': in people with persistent pain after back surgery, gabapentin worked no better than a dummy pill [12], and in older patients with chronic low back pain pregabalin helped the nerve-pain subgroup while plain painkillers helped the rest [16]. A head-to-head back-pain trial compared the two drugs to each other but had no dummy-pill group, so it cannot show benefit over nothing [10]. Against the claim, an observational study found gabapentinoids reduced chronic pain more than opioids [23], and the drugs eased pain in rat muscle-pain experiments [28], but these are weaker kinds of evidence. The key limitation is that no trial in the corpus directly compares a gabapentinoid to a dummy pill in people with purely non-nerve chronic pain, so the picture is suggestive rather than settled.
The included primary trials point toward minimal benefit: gabapentin was no different from placebo on any outcome in failed-back-surgery syndrome [12], and pregabalin was effective for the neuropathic rather than the non-neuropathic low-back-pain subgroup [16]. The only head-to-head low-back-pain trial [10] showed within-class pain reduction but had no placebo arm, so it cannot establish benefit over placebo. Contrary primary data exist but are weaker in design: an observational Medicare cohort associated gabapentinoids with larger chronic-pain reduction than opioids in a dose-dependent manner [23], and pregabalin reduced hyperalgesia in rat muscle-pain models [28]. A retrospective lumbar-fusion cohort found worse outcomes in chronic gabapentinoid users [24], though this is confounded by indication. The contested point: The division is between the methodologically stronger placebo-controlled or comparative RCTs that lean toward minimal benefit ([12], [16]) and a real but weaker contrary signal of benefit from observational [23] and preclinical [28] evidence. It also turns on population: the cleanest null [12] required a neuropathic component, so no included trial tests a purely non-neuropathic population against placebo.
All 31 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Chronic Pain Pharmacotherapy, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The cleanest placebo-controlled null [12] enrolled only patients with a neuropathic pain component (PainDetect, radiating leg pain), so it does not test a purely non-neuropathic population and is indirect support for a strictly non-neuropathic claim.
No included primary trial compares a gabapentinoid to placebo in pure non-neuropathic chronic pain: [10] is head-to-head without placebo and [16] compares pregabalin vs opioid, so absolute benefit over placebo in non-neuropathic pain is not directly established.
Where it remains uncertain. An observational cohort found gabapentinoids reduced chronic pain more than opioids in a dose-dependent manner [23], directly opposing the claim, but it is not placebo-controlled; the strongest confirmatory statements sit in excluded review articles [3][21][26].
Aleatory
The supporting trials are small ([12] n=32, [10] n=64, [16] n=65), so random variation in pain outcomes is large relative to any true effect.
Epistemic
The corpus contains no RCT comparing a gabapentinoid to placebo in a purely non-neuropathic chronic-pain population; [12] required a neuropathic component, [10] had no placebo arm, [16] compared vs opioid.
Inferential
[23] associates gabapentinoids with larger pain reduction than opioids, but as a non-randomised comparison versus opioids (not placebo) the direction of benefit cannot be cleanly attributed.
The load-bearing papers from a corpus of 31, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Head-to-head in nonspecific LBP with no placebo arm; shows within-class reduction but cannot establish benefit over placebo — neutral.
“This is the first trial aimed at comparing gabapentin with pregabalin in NLBP. Although the results are preliminary, in our pilot study pregabalin was found to be superior in pain reduction”
Panel auditInternal validity: low · scope of inference: Relative effects of two gabapentinoids on low back pain.Key limitations: no placebo · pilot · small n
Placebo-controlled RCT null for gabapentin in a chronic back-pain (FBSS) population — supports minimal benefit; caveat that enrolment required a neuropathic component.
“No difference was detected between treatments on any outcome measure, including the primary (least square mean difference in NRS: -0.01 confidence interval: [-0.22 to 0.20]).”
Panel auditInternal validity: medium · scope of inference: Failed back surgery syndrome with a neuropathic/radicular component.Key limitations: small n · neuropathic component enriched · single syndrome
RCT indicating pregabalin was not the effective agent for non-neuropathic low back pain — supports the claim.
“Pregabalin was effective for LBP with neuropathic pain, whereas opioids were effective for non-neuropathic pain.”
Panel auditInternal validity: low · scope of inference: Chronic low back pain in patients aged 65+.Key limitations: small n · subgroup finding · no placebo
Cohort showing no outcome advantage for chronic gabapentinoid users; confounded by indication.
“Chronic preoperative use of GPs may lead to inferior outcomes when compared with GP-naive patients”
Panel auditInternal validity: low · scope of inference: Lumbar fusion outcomes by chronic preoperative gabapentinoid/opioid use.Key limitations: confounding by indication · retrospective · surgical outcome not pain-relief trial
4 of 31 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Direct human RCT evidence leans toward minimal benefit, but the supporting trials are small and caveated and the contrary signals, though weaker, are real, so the corpus carries a Likely rather than Established verdict.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Placebo-controlled RCT in pure non-neuropathic chronic pain. The claim concerns non-neuropathic pain, yet the cleanest null [12] required a neuropathic component and no included trial has a placebo arm in a purely non-neuropathic population. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A double-blind, placebo-controlled RCT of gabapentin or pregabalin in patients screened to exclude a neuropathic component, with a validated pain outcome.
Open question: Does a gabapentinoid outperform placebo for pain in patients with purely non-neuropathic chronic pain? Why it is still open: The cleanest included null [12] enrolled patients with a neuropathic component, [10] had no placebo arm, and [16] compared vs opioid, so no included trial answers this directly.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19